Tacrolimus (FK506) and cyclosporine (cyclosporin A, CsA) are cornerstone immunosuppressive agents administered to solid organ transplant recipients to prevent and treat allograft rejection. The discovery of cyclosporine in the 1970s, and its entry into the collection of immunosuppressants in the early 1980s, was a major breakthrough in medicine. Cyclosporine was the most successful antirejectio...

The relative susceptibility of different developmental stages of Plasmodium berghei to cyclosporine was investigated in vivo. Within 12 h of receiving a single 25-mg/kg (body weight) dose of cyclosporine, mice with patent P. berghei infections uniformly exhibited a rapid fall in asexual parasite stages. Initially, ring forms and mature schizonts disappeared. Subsequently, trophozoites disappear...

BACKGROUND The treatment of severe ulcerative colitis (UC) flares includes measures such as hospitalization and intravenous steroids. Despite this, a quarter of patients are refractory to treatment. Given the availability of new therapeutic strategies in patients with steroid-refractory UC (cyclosporine, infliximab, apheresis, surgery) it is necessary to predict which treatment will be most eff...

psoriasis and the ability to treat this disease with immunosuppressants has greatly expanded in the past few decades. With respect to the pathogenesis of psoriasis, the entire refocusing from keratinocyte hyperproliferation to immunology started with the serendipitous discovery that immune modulating agents, namely cyclosporine, led to undeniable and often dramatic psoriasis improvement with no...

Previous studies have shown that the immunosuppressant drug cyclosporine A attenuates arterial baroreceptor function. This study investigated whether the modulatory effect of cyclosporine on baroreceptor function involves inhibition of the baroreflex-facilitatory effect of testosterone. The role of cardiac autonomic control in cyclosporine-testosterone baroreflex interaction was also investigat...

In the Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial-Extended Criteria Donors (BENEFIT-EXT), extended criteria donor kidney recipients were randomized to receive belatacept-based (more intense [MI] or less intense [LI]) or cyclosporine-based immunosuppression. In prior analyses, belatacept was associated with significantly better renal function com...

Development of new oral cyclosporine formulation using cyclodextrin tetrapolymer (Pαβγ-CD) in attempt to enhance its stability and dissolution rate.Two spray-dried dispersion formulations containing poorly water-soluble cyclosporine (CsA) were prepared with cyclodextrin tetrapolymer in water (FH2O) and ethanol (FEOH) then characterized by scanning electron microscopy, powder X-ray diffraction, ...

Cyclosporine concentrations in whole blood and plasma were determined in 25 samples from renal-transplant patients. The portion of cyclosporine carried in plasma varied widely, from 9 to 58%. Radioimmunoassay and liquid chromatography both revealed a statistically significant inverse correlation between hematocrit and the plasma fraction of cyclosporine in the circulating blood. Regression anal...